New combo therapy aims to slow kidney damage in IgA disease
NCT ID NCT07585981
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests whether adding budesonide capsules early to standard blood-pressure and sugar-lowering drugs can reduce protein leakage in the urine of people with IgA nephropathy, a kidney disease. About 30 adults with newly diagnosed, moderate disease will receive the combination for 9 months, then taper off budesonide while continuing the other drugs for 3 more months. The main goal is to see if proteinuria drops after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.